Compared to its successful counterpart, the PACIFIC trial in locally advanced non-small cell lung cancer (NSCLC) that incorporated PD-L1 blockade as consolidation treatment after CRT [75], JAVELIN 100 has aroused massive discussions on its failure. The gene discussed is CD274; the disease is non-small cell lung carcinoma.